Blog Archive

Fighting Hyperglycemia and Type II Diabetes with Technology


The effects of poorly controlled blood glucose levels have long been known to cause serious co-morbidities such as blindness, impotence, renal and cardiac dysfunction, amputations, coma and death. Hyperglycemia also occurs in non-diabetic patients in the hospital as a result of stress, surgical procedures, medication, and hormonal imbalances.

These complications are associated with longer hospital stays, higher admission rates, less change to be discharged to home, higher rate of mortality, higher rate of morbidity, higher costs, more procedures, more medications, more infections, and complications in pregnancies.

Even just two hours of hyperglycemia can result and impaired white blood cell function for weeks, causing greater infection rate, impaired wound health, increased length of stay, higher operative morbidities, and higher hospital mortality. In surgical patients, one preoperative glucose > 220 mg/dL can result in 5.8 times greater chance of experiencing a nosocomial infection.

Glytec has developed the G+ Enterprise Edition, which provides real-time insulin dosing recommendations while taking into account all pertinent patient information: demographics, health and laboratory results. It considers physiological pathways that include risk factors and relevant interventions with improved outcomes as a target. Individual care guidelines result in improved patient outcomes and more efficient use of healthcare resources. The system also provides a reporting platform and system that measures compliance requirements for patients and providers.

Please join us on June 7th for a special luncheon presentation at The Yale Club in New York City and meet Trefor Thomas, CEO & President of Glytec.  Trefor will discuss how this innovative technology has the potential to not only save lives, but dramatically reduce costs for both the patient and the heath care providers.  In addition, you'll learn how this approach can easily be replicated and used to manage other  diseases.

This event is hosted by The Global Leaders and sponsored by M.M. Dillon & Companywww. and seating is extremely limited.



About Trefor Thomas, President and Chief Executive Officer of GlucoTec, Inc.  

Trefor Thomas was educated in England and graduated from Gonville & Caius College, Cambridge n 1968 with a law degree.  He joined the central Legal Department of The Rank Organization, PLC in London in 1971, and in 1974, he became Executive Assistant to the Group Chairman, principally responsible for supervising exchange control compliance for the worldwide investments, mergers and acquisitions of the Group. In addition to those responsibilities, in 1975 he was appointed General Manager of Rank City Wall, a property development and management arm of the Rank Group, with operations and development of commercial offices hotels, and industrial warehousing estates in the United Kingdom, Belgium, France, and Canada. In 1982, he was sent to Myrtle Beach, South Carolina to head up development of an oceanfront resort development, which is still the largest and most successful meeting and tourist resort in Myrtle Beach. 

Following management changes in the London office in 1991, Trefor Thomas left the Rank Group and became a partner in Nelson Mullins Riley & Scarborough LLP, in South Carolina, after graduating in less than one year from the University of South Carolina Law School.  He was named as South Carolina Pro-Bono Lawyer of the Year in 1995.  He also served as the Chairman of the South Carolina Bar Association Technology Committee in 1995.

He became Chief Staff Attorney for Horry County, South Carolina from 1998 until 2000, when he moved to Parker Poe Adams & Bernstein, LLP in its Columbia, South Carolina office. After two years in Columbia, in 2002 Trefor Thomas returned to live in Myrtle Beach, and became General Counsel to a group of companies operating premium golf courses and hotel businesses.

In 2008 he became President of GlucoTec, Inc., a company designing and implementing software for glycemic management in critically ill hospital patients, and was appointed Chief Executive Officer in April 2011.